Sudha Visvanathan Selected Research

risankizumab

1/2019	Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
11/2018	Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
10/2018	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
1/2018	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
1/2017	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
1/2017	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
7/2015	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sudha Visvanathan Research Topics

Disease

10	Rheumatoid Arthritis 01/2019 - 09/2006
9	Inflammation (Inflammations) 01/2022 - 07/2007
8	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 04/2009
7	Ankylosing Spondylitis 01/2018 - 03/2007
5	Crohn Disease (Crohn's Disease) 01/2020 - 01/2017
5	Chronic Obstructive Pulmonary Disease (COPD) 01/2015 - 06/2011
4	Infections 11/2023 - 03/2007
4	Necrosis 10/2017 - 07/2009
3	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 09/2010 - 09/2007
2	Skin Diseases (Skin Disease) 04/2021 - 01/2020
2	Thrombosis (Thrombus) 11/2020 - 03/2003
2	Body Weight (Weight, Body) 01/2017 - 05/2007
2	Emphysema 10/2013 - 06/2011
2	Psoriatic Arthritis 01/2013 - 04/2009
2	Giant Cell Arteritis (Horton Disease) 11/2011 - 05/2007
1	Lupus Nephritis 11/2023
1	Atopic Dermatitis (Atopic Eczema) 10/2022
1	Systemic Scleroderma (Systemic Sclerosis) 01/2020
1	Colitis 01/2020
1	Disease Progression 01/2020
1	Bone Resorption 01/2019
1	Ileitis 10/2018
1	Ulcerative Colitis 10/2017
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2015
1	Neoplasms (Cancer) 01/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2012
1	Sarcoidosis (Schaumann Disease) 06/2011
1	Lung Diseases (Lung Disease) 06/2011
1	Asthma (Bronchial Asthma) 06/2011
1	Tuberculosis (Tuberculoses) 06/2011
1	Fibrosis (Cirrhosis) 06/2011
1	Fatigue 08/2009
1	Anemia 08/2009
1	Asthenopia (Eyestrain) 08/2009
1	Nail Diseases (Nail Disease) 04/2009
1	Back Pain (Backache) 11/2008
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2003

Drug/Important Bio-Agent (IBA)

14	Biomarkers (Surrogate Marker)IBA 11/2023 - 07/2007
12	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 09/2006
11	Infliximab (Remicade)FDA Link 09/2010 - 09/2006
9	golimumab FDA Link 01/2013 - 04/2008
8	Interleukin-23 (Interleukin 23)IBA 01/2024 - 07/2015
8	Monoclonal AntibodiesIBA 11/2023 - 07/2009
7	risankizumabIBA 01/2019 - 07/2015
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2009 - 03/2007
3	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2019
3	Immunoglobulin G (IgG)IBA 01/2017 - 03/2003
2	BI 655064IBA 11/2023 - 01/2019
2	GlucocorticoidsIBA 11/2023 - 05/2007
2	spesolimabIBA 01/2023 - 01/2022
2	Peroxidase (Myeloperoxidase)IBA 04/2021 - 01/2020
2	AntibodiesIBA 11/2020 - 03/2007
2	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2015
2	Immunoglobulin M (IgM)IBA 01/2019 - 09/2006
2	Ustekinumab (CNTO 1275)FDA Link 01/2019 - 01/2017
2	Interleukin-23 Subunit p19IBA 01/2019 - 11/2018
2	Interleukin-12 (IL 12)IBA 01/2019 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 08/2009
2	Fibrinogen (Factor I)FDA Link 02/2013 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 01/2013 - 01/2012
2	C-Reactive ProteinIBA 05/2012 - 08/2009
2	Anticardiolipin AntibodiesIBA 09/2006 - 03/2003
1	CD40 Ligand (CD40L)IBA 11/2020
1	Dextrans (Dextran)FDA Link 01/2020
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2020
1	Immunoglobulin A (IgA)IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	LigandsIBA 01/2019
1	Rheumatoid FactorIBA 01/2019
1	AutoantibodiesIBA 01/2019
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 01/2019
1	Tumor Necrosis Factor InhibitorsIBA 01/2017
1	P-2 (P 2)IBA 07/2015
1	Receptor for Advanced Glycation End ProductsIBA 10/2013
1	Phenobarbital (Luminal)FDA Link 02/2013
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2013
1	Apolipoprotein C-IIIIBA 01/2013
1	AdiponectinIBA 01/2013
1	Blood Proteins (Serum Proteins)IBA 01/2012
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2012
1	HaptoglobinsIBA 06/2011
1	ParaffinIBA 06/2011
1	Transforming Growth Factors (Transforming Growth Factor)IBA 06/2011
1	Hemoglobins (Hemoglobin)IBA 08/2009
1	Interleukin-18 (Interleukin 18)IBA 07/2009
1	E-SelectinIBA 07/2009
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 07/2009
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 07/2009
1	ametantrone (HAQ)IBA 04/2009
1	Etanercept (Enbrel)FDA Link 07/2007
1	CytokinesIBA 07/2007
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 05/2007
1	Peptides (Polypeptides)IBA 03/2003

Therapy/Procedure

11	Therapeutics 10/2018 - 03/2007
4	Subcutaneous Injections 01/2017 - 11/2008
2	Aftercare (After-Treatment) 01/2010 - 07/2009
1	Stem Cell Transplantation 04/2019
1	Immunomodulation 06/2011
1	Retreatment 03/2007